Samuel G Oltman, ND, RMSK
A recent randomized controlled trial published in Arthroscopy (February 2025) investigated the efficacy of microfragmented adipose tissue (MFAT) injections, containing mesenchymal stem cells, for patients with symptomatic knee osteoarthritis (OA) (1). The study aimed to evaluate whether MFAT could provide significant pain relief and improve joint functionality compared to steroids and a saline control over a one-year period.
Study Overview
Conducted by Richter et al., the trial included patients diagnosed with knee OA who were experiencing persistent symptoms. Participants were randomly assigned to receive either an intra-articular injection of MFAT, a cortisone injection, or a saline solution. The primary outcomes measured were changes in pain levels and joint function over 12 months.
Key Findings
Pain Reduction: Patients receiving MFAT injections reported a significant decrease in pain compared to the saline group throughout the one-year follow-up.
Improved Functionality: Those treated with MFAT also demonstrated notable improvements in joint function, suggesting enhanced mobility and reduced stiffness.
Sustained Benefits: The therapeutic effects of MFAT were maintained over the entire study period, indicating its potential as a long-term treatment option for knee OA.
Context in Knee Osteoarthritis Treatment
Knee OA is a prevalent condition characterized by joint degeneration, leading to pain and reduced function. Traditional treatments range from conservative approaches like physical therapy and medications to surgical interventions such as total knee replacement. However, these options may not be suitable for all patients due to varying efficacy, potential risks, and recovery times.
The use of adipose-derived mesenchymal stem cells (AD-MSCs) has emerged as a promising alternative. Previous studies have highlighted the potential of AD-MSCs in reducing pain and improving quality of life for knee OA patients. For instance, a meta-analysis published in Stem Cell Research & Therapy (2021) reported significant pain reduction and functional improvement following AD-MSC therapy (2).
The current study by Richter et al. adds to this growing body of evidence by demonstrating the sustained benefits of MFAT injections over a one-year period. These findings suggest that MFAT could serve as a viable minimally invasive treatment option for patients seeking alternatives to surgery.
Conclusion
The trial underscores the potential of MFAT injections in managing knee OA symptoms effectively over the long term. As research progresses, incorporating such regenerative therapies could revolutionize the treatment landscape for knee osteoarthritis, offering patients relief with fewer risks and shorter recovery times compared to traditional surgical methods. Contact us today to learn more.
References:
Richter DL, Harrison JL, Faber L, et al. Microfragmented adipose tissue injection reduced pain compared with a saline control among patients with symptomatic osteoarthritis of the knee during 1-year follow-up: a randomized controlled trial. Arthroscopy. 2025;41(2):248-260.
Agarwal N, Mak C, Bojanic C, To K, Khan W. Meta-analysis of adipose tissue derived cell-based therapy for the treatment of knee osteoarthritis. Cells. 2021;10(6):1365.
Comments